KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortizatization of Intangibles (2016 - 2023)

Historic Amortizatization of Intangibles for Travere Therapeutics (TVTX) over the last 13 years, with Q4 2023 value amounting to $2.3 million.

  • Travere Therapeutics' Amortizatization of Intangibles rose 12238.51% to $2.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.7 million, marking a year-over-year increase of 71742.86%. This contributed to the annual value of $4.5 million for FY2024, which is 3917.65% down from last year.
  • According to the latest figures from Q4 2023, Travere Therapeutics' Amortizatization of Intangibles is $2.3 million, which was up 12238.51% from $1.9 million recorded in Q3 2023.
  • In the past 5 years, Travere Therapeutics' Amortizatization of Intangibles registered a high of $2.3 million during Q4 2023, and its lowest value of -$697000.0 during Q4 2021.
  • Its 5-year average for Amortizatization of Intangibles is $161333.3, with a median of -$155500.0 in 2020.
  • As far as peak fluctuations go, Travere Therapeutics' Amortizatization of Intangibles soared by 29509.8% in 2019, and later plummeted by 202222.22% in 2020.
  • Travere Therapeutics' Amortizatization of Intangibles (Quarter) stood at $9000.0 in 2019, then crashed by 2022.22% to -$173000.0 in 2020, then crashed by 302.89% to -$697000.0 in 2021, then skyrocketed by 246.77% to $1.0 million in 2022, then surged by 122.39% to $2.3 million in 2023.
  • Its last three reported values are $2.3 million in Q4 2023, $1.9 million for Q3 2023, and $1.0 million during Q4 2022.